2019 California Code
Health and Safety Code - HSC
DIVISION 2 - LICENSING PROVISIONS
CHAPTER 4 - Human Whole Blood, Human Whole Blood Derivatives, and Other Biologics
ARTICLE 7 - Blood Donations
Section 1625.

As used in this article:

(a)  “Blood” means human whole blood or components of human blood, including plasma, which are prepared from human whole blood by physical, rather than chemical processes, but does not include blood derivatives manufactured or processed for industrial use.

(b)  “Cytapheresis” means the separation and collection of blood cells by hemapheresis.

(c)  “Hemapheresis” means the removal of whole blood from a donor, separation of the blood into components, retention of the desired components, and return of the recombined remaining elements to the donor.

(d)  “Industrial use” means a use of blood in which the blood is modified by physical or chemical means to produce derivatives for therapeutic or pharmaceutic biologics, laboratory reagents, or in vitro diagnostics.

(e)  “Paid donor” means a person who donates blood and who receives payment in return for the donation of such blood.

(f)  “Payment” means the transfer by a blood bank to any person of money or any other valuable consideration which can be converted to money by the recipient, except that payment shall not include any of the following:

(1)  Cancellation or refund of the nonreplacement fees or related blood transfusion charges.

(2)  Blood assurance benefits to a person as a result of a blood donation to a donor club or blood assurance program.

(3)  Time away from employment, with or without pay, granted by an employer to an employee in order to donate blood.

(g)  “Person” means any individual, blood bank, hospital, firm, corporation, or any other entity.

(h)  “Transfusion” means a use of blood in which the blood is administered to a human being for treatment of sickness or injury.

(Amended by Stats. 1986, Ch. 1007, Sec. 2.)